ARTICLE | Product Development
COVID Quick Takes: ACIP readies to discuss vaccine for ages 12-15; plus Novavax, Moderna, Vectura
May 7, 2021 2:19 AM UTC
In a signal that COVID vaccines could soon be available for Americans as young as 12, CDC’s Advisory Committee on Immunization Practices (ACIP) has revealed that the emergency meeting scheduled for May 12 will discuss Comirnaty COVID-19 vaccine from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) in children ages 12-15.
Novavax Inc. (NASDAQ:NVAX) will deliver 350 million doses of its recombinant protein-based COVID vaccine NVX-CoV2373 to Gavi, the Vaccine Alliance, starting in 3Q21, with 1.1 billion doses to become available to countries participating in COVAX. Under a separate purchase agreement with Gavi, the Serum Institute of India is expected to manufacture and deliver 750 million doses of Novavax’s vaccine...